BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo PE, Azria D, Pèlegrin A, Larbouret C, Chardès T. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer 2019;145:1838-51. [PMID: 30882895 DOI: 10.1002/ijc.32273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S, Sala G. EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics 2021;13:483. [PMID: 33918158 DOI: 10.3390/pharmaceutics13040483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Aschmoneit N, Kühl L, Seifert O, Kontermann RE. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. J Immunother Cancer 2021;9:e003616. [PMID: 34782429 DOI: 10.1136/jitc-2021-003616] [Reference Citation Analysis]
3 Gandullo-Sánchez L, Capone E, Ocaña A, Iacobelli S, Sala G, Pandiella A. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. EMBO Mol Med 2020;12:e11498. [PMID: 32329582 DOI: 10.15252/emmm.201911498] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
4 Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Mol Cancer Ther 2020;19:157-67. [PMID: 31597712 DOI: 10.1158/1535-7163.MCT-18-1302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
5 Haikala HM, Jänne PA. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Clin Cancer Res 2021;27:3528-39. [PMID: 33608318 DOI: 10.1158/1078-0432.CCR-20-4465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gong L, Zhang Y, Liu C, Zhang M, Han S. Application of Radiosensitizers in Cancer Radiotherapy. Int J Nanomedicine 2021;16:1083-102. [PMID: 33603370 DOI: 10.2147/IJN.S290438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev 2019;144:35-56. [PMID: 31279729 DOI: 10.1016/j.addr.2019.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
8 Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. MAbs 2021;13:1914883. [PMID: 33876707 DOI: 10.1080/19420862.2021.1914883] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Aschmoneit N, Steinlein S, Kühl L, Seifert O, Kontermann RE. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Sci Rep 2021;11:13880. [PMID: 34230555 DOI: 10.1038/s41598-021-93351-0] [Reference Citation Analysis]